Drug Profile
Research programme: retinal disease therapeutics - Avixgen
Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Avixgen
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Retinal disorders
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Retinal-disorders in South Korea
- 03 Sep 2018 Avixgen plans a phase I trial for Age-related macular degeneration in South Korea
- 07 Sep 2017 Preclinical trials in Retinal disorders in South Korea (unspecified route)